# Goserelin

## Zoladex Depot 3.6mg

| TAH Drug Code      | [**IZOL**](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IZOL)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|:-------------------|:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Breast cancer, advanced. Endometrial thinning. Endometriosis. Prostate cancer, advanced. Prostate cancer, stage B2 to C (in combination with an antiandrogen and radiotherapy; begin 8 weeks prior to radiotherapy): Males. Artificial assisted reproduction.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Dosing             | 3.6 mg subQ every 28 days [Endometriosis] 3.6 mg subQ every 28 days for up to 6 months [Endometrial thinning] Two 3.6 mg subQ injections given 4 weeks apart with endometrial ablation surgery performed within 2 weeks of the second injection [Uterine fibroid with anemia] 3.6 mg subQ with supplementary iron for up to 3 months before surgery                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Contraindications  | Hypersensitivity to goserelin, gonadotropin releasing hormone (GnRH), GnRH agonist analogues, or any component of the product. Pregnancy in females with endometriosis or endometrial thinning, as drug may cause fetal harm and has increased risk of pregnancy loss; must exclude pregnancy prior to therapy and use nonhormonal contraception during therapy and 12 weeks after discontinuation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Adverse Effects    | Common Cardiovascular: Peripheral edema (21% ) Dermatologic: Acne (42% ), Seborrhea (26% ), Sweating (1% to 45% ) Endocrine metabolic: Atrophy of breast (33% ) Neurologic: Headache (men, greater than 1% to less than 5%; women, 32% to 75% ) Psychiatric: Depression (men, greater than 1% to less than 5%; women, 54% ), Mood swings (60% ) Reproductive: Erectile dysfunction (18% ), Flushing (46% to 96% ), Reduced libido (47.7% to 61% ), Sexual dysfunction (21% ), Vaginitis (5% to 75% ) Other: Pain (8% to 17% ) Serious Cardiovascular: Cardiovascular event risk, Congestive heart failure (5% ), Hemorrhagic shock, Myocardial infarction (greater than 1% to less than 5% ), Prolonged QT interval Dermatologic: Injection site hemorrhage Endocrine metabolic: Diabetes mellitus (10.9% to 22.2% ), Pituitary apoplexy (rare ), Pituitary tumor (rare ), Tumor flare (23% ) Hematologic: Hemorrhage Immunologic: Anaphylaxis, Hypersensitivity reaction (1% or greater ) Neurologic: Cerebrovascular accident (greater than 1% to less than 5% ) Renal: Renal impairment (greater than 1% to less than 5% ) Respiratory: Chronic obstructive pulmonary disease (5% ) Other: Tumor flare (23% ) |
| Pregnancy          | Unknown                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Lactation          | Unknown                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |

## ZOLADEX LA 10.8mg DEPOT (3 Months)

| TAH Drug Code      | [**IZOL1**](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IZOL1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|:-------------------|:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Treatment of prostate cancer. Treatment of breast cancer for premenopausal women.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Dosing             | 10.8 mg subQ every 12 weeks                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Contraindications  | Hypersensitivity to goserelin, gonadotropin releasing hormone (GnRH), GnRH agonist analogues, or any component of the product. Pregnancy in females with endometriosis or endometrial thinning, as drug may cause fetal harm and has increased risk of pregnancy loss; must exclude pregnancy prior to therapy and use nonhormonal contraception during therapy and 12 weeks after discontinuation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Adverse Effects    | Common Cardiovascular: Peripheral edema (21% ) Dermatologic: Acne (42% ), Seborrhea (26% ), Sweating (1% to 45% ) Endocrine metabolic: Atrophy of breast (33% ) Neurologic: Headache (men, greater than 1% to less than 5%; women, 32% to 75% ) Psychiatric: Depression (men, greater than 1% to less than 5%; women, 54% ), Mood swings (60% ) Reproductive: Erectile dysfunction (18% ), Flushing (46% to 96% ), Reduced libido (47.7% to 61% ), Sexual dysfunction (21% ), Vaginitis (5% to 75% ) Other: Pain (8% to 17% ) Serious Cardiovascular: Cardiovascular event risk, Congestive heart failure (5% ), Hemorrhagic shock, Myocardial infarction (greater than 1% to less than 5% ), Prolonged QT interval Dermatologic: Injection site hemorrhage Endocrine metabolic: Diabetes mellitus (10.9% to 22.2% ), Pituitary apoplexy (rare ), Pituitary tumor (rare ), Tumor flare (23% ) Hematologic: Hemorrhage Immunologic: Anaphylaxis, Hypersensitivity reaction (1% or greater ) Neurologic: Cerebrovascular accident (greater than 1% to less than 5% ) Renal: Renal impairment (greater than 1% to less than 5% ) Respiratory: Chronic obstructive pulmonary disease (5% ) Other: Tumor flare (23% ) |
| Pregnancy          | Unknown                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Lactation          | Unknown                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |

